Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc. (MRTX) Revenue
Annual & quarterly revenue history · segment & region breakdown
MRTX · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsMirati Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.04B, a decrease of 82.75% year-over-year from $0.01B in FY2022.
Revenue trend
2022 – 2003 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2022-12-31 | $0.01B | -$0.06B | -82.75% |
| 2021-12-31 | $0.07B | +$0.06B | +438.08% |
| 2020-12-31 | $0.01B | +$0.01B | +301.74% |
| 2019-12-31 | $0.00B | -$0.01B | -74.20% |
| 2018-12-31 | $0.01B | +$0.01B | — |
| 2017-12-31 | $0.00B | +$0.00B | — |
| 2016-12-31 | $0.00B | +$0.00B | — |
| 2015-12-31 | $0.00B | +$0.00B | — |
| 2014-12-31 | $0.00B | +$0.00B | — |
| 2013-12-31 | $0.00B | -$0.00B | -100.00% |
Compare revenue vs peers
BiotechnologyCompare MRTX revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Mirati Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Mirati Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Mirati Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
MRTX revenue · 4 questionsMRTX's trailing twelve-month (TTM) revenue is $0.04B. That is a decrease of 82.75% year-over-year from $0.01B in FY2022.
▸ Source: FMP · Mirati Therapeutics, Inc. SEC filings · GAAP · Mirati Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026